STRASBOURG, France, July 24 /PRNewswire-FirstCall/ -- Transgene S.A. announces today final results of the exercise of warrants issued as part of a capital increase in July 2005. Over the exercise period (15th July 2005 to 17th July 2006), 3, 555, 074 warrants, or 76.3 %, of a total 4,657,500 warrants were exercised. The July 2005 capital increase consisted of an offering of shares with warrants (actions a bon de souscription d’actions or ABSA), two warrants enabling holders to subscribe to one new share at EUR 8.05 on or before July 17th 2006.
Transgene received EUR 14.3 million through the exercise of the warrants leading to the issuance of 1, 777, 537 new shares. Cash, cash equivalents and short term investments after the exercise of warrants amount to EUR 29.3 million.
“Despite difficult market conditions for the last few months, particularly for small- and midcap companies, a large majority of investors chose to exercise their warrants and enable the company to pursue its developments,” said Philippe Archinard, Chief Executive of Transgene. “I thank them for their renewed confidence in the company.”
About Transgene:
Transgene is a France-based biopharmaceutical company dedicated to the development of therapeutic vaccines and immunotherapeutic products in oncology and infectious diseases. The company has three compounds in Phase II trials and one compound in Phase I studies. Transgene has bio-manufacturing production capacities for viral-based vectors and technologies available for out-licensing. For further information about Transgene, please visit www.transgene.fr
Press Contacts: Transgene Capital MS&L Image 7 Philippe Poncet Shaun Brown Estelle Guillot-Tantay +33-88-27-91-21 Mary Clark Tiphaine Hecketsweiler www.transgene.fr +44(0)20-7307-5330 +33-1-53-70-74-93
Transgene S.A.
CONTACT: Press Contacts: Transgene, Philippe Poncet, +33-88-27-91-21;Capital MS&L, Shaun Brown, Mary Clark, +44(0)20-7307-5330; Image 7, EstelleGuillot-Tantay, Tiphaine Hecketsweiler
